alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT 31.1

                            CERTIFICATION PURSUANT TO
                  SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, R. B.Harris, certify that:

1. I have reviewed this quarterly  report on Form 10-QSB/A of Sales  Strategies,
Inc.;

2.  Based on my  knowledge,  this  annual  report  does not  contain  any untrue
statement of a material fact or omit to state a material fact  necessary to make
the statements made, in light of the  circumstances  under which such statements
were made,  not  misleading  with  respect to the period  covered by this annual
report;

3.  Based  on my  knowledge,  the  financial  statements,  and  other  financial
information  included  in this annual  report,  fairly  present in all  material
respects the financial  condition,  results of operations  and cash flows of the
registrant as of, and for, the periods presented in this annual report;

4.  The  registrant's  other  certifying  officers  and  I are  responsible  for
establishing and maintaining  disclosure  controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

a) designed  such  disclosure  controls and  procedures  to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others  within those  entities,  particularly  during the
period in which this annual report is being prepared;

b) evaluated  the  effectiveness  of the  registrant's  disclosure  controls and
procedures  as of a date  within 90 days prior to the filing date of this annual
report (the "Evaluation Date"); and

c) presented in this quarterly report our conclusions about the effectiveness of
the  disclosure  controls  and  procedures  based  on our  evaluation  as of the
Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation,  to the registrant's auditors and the audit committee of
registrant's board of directors:

a) all significant  deficiencies in the design or operation of internal controls
which  could  adversely  affect the  registrant's  ability  to record,  process,
summarize and report  financial data and have  identified  for the  registrant's
auditors any material weaknesses in internal controls; and

b) any  fraud,  whether  or not  material,  that  involves  management  or other
employees who have a significant role in the registrant's internal controls; and

6. The  registrant's  other  certifying  officers  and I have  indicated in this
annual report whether or not there were significant changes in internal controls
or in other factors that could significantly affect internal controls subsequent
to the date of our most recent evaluation, including any corrective actions with
regard to significant deficiencies and material weaknesses.

Date: September 22, 2003                 /s/ R. B. Harris
                                         --------------------------
                                         R. B. Harris
                                         President/ CEO/Director
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
AUDITED CONSOLIDATED FINANCIAL DATA OF THE COMPANY AS OF JULY 26, 1996 AND FOR
THE YEAR THEN ENDED AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH 
FINANCIAL DATA.
</LEGEND>
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          JUL-26-1996
<PERIOD-START>                             JUL-29-1995
<PERIOD-END>                               JUL-26-1996
<EXCHANGE-RATE>                                      1
<CASH>                                             793
<SECURITIES>                                         0
<RECEIVABLES>                                    9,234
<ALLOWANCES>                                       373
<INVENTORY>                                      9,760
<CURRENT-ASSETS>                                20,608
<PP&E>                                             476
<DEPRECIATION>                                   1,191
<TOTAL-ASSETS>                                  21,112
<CURRENT-LIABILITIES>                           15,976
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             3
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                    21,112
<SALES>                                         73,456
<TOTAL-REVENUES>                                73,456
<CGS>                                           51,489
<TOTAL-COSTS>                                   51,489
<OTHER-EXPENSES>                                17,036
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 282
<INCOME-PRETAX>                                  4,649
<INCOME-TAX>                                     1,800
<INCOME-CONTINUING>                              2,849
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     2,849
<EPS-PRIMARY>                                      .31
<EPS-DILUTED>                                      .31
        

</TABLE>
REGULATORY EVALUATIO

Directorate Identifier: 2010-NM-068-AD

Costs: Labor per airplane (I work hour(s) x $85/hour) Cost per airplane Number ofU,S.-registered airplanes Total fleet cost $ $

Executive Order 12866: Could theAD be considered a "significant regulatory action"? YES () explain NO (X) 

### DOT Regulatory Policies and Procedures: Isthe AD significant? YES () explain NO (X) Regulatory Flexibility Act: Will the AD have a significant economic impact on a substantial number of small entities? YES () explain NO (X) Intrastate Aviation inAlaska: This AD could affect intrastate aviation inAlaska. Isitappropriate to include specific requirements for aircraft operated inAlaska, where aviation might be the only mode of transportation? YES () explain NO (X)
[Federal Register Volume 89, Number 23 (Friday, February 2, 2024)]
[Notices]
[Page 7403]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-02050]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Center for Complementary & Integrative Health; Notice of 
Closed Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Center for Complementary and 
Integrative Health Special Emphasis Panel; Clinical and Data 
Coordinating Center Applications for NCCIH Multi-Site Clinical 
Trials of Mind and Body Interventions.
    Date: March 1, 2024.
    Time: 3:00 p.m. to 5:00 p.m.
    Agenda: To review and evaluate cooperative agreement 
applications.
    Place: National Institutes of Health, National Center for 
Complementary and Integrative Health, Democracy II, 6707 Democracy 
Blvd., Bethesda, MD 20892 (Virtual).
    Contact Person: Baila S. Hall, Ph.D., Scientific Review Officer, 
Office of Scientific Review, Division of Extramural Activities, 
National Center for Complementary and Integrative Health, National 
Institutes of Health, 6707 Democracy Blvd., Suite 401, Bethesda, MD 
20892, (301) 443-9285, <a href="/cdn-cgi/l/email-protection#b3d1d2dadfd29ddbd2dfdff3dddadb9dd4dcc5"><span class="__cf_email__" data-cfemail="a7c5c6cecbc689cfc6cbcbe7c9cecf89c0c8d1">[email protected]</span></a>.
    Marta V. Hamity, Ph.D., Scientific Review Officer, Office of 
Scientific Review, Division of Extramural Activities, National 
Center for Complementary and Integrative Health, National Institutes 
of Health, 6707 Democracy Boulevard, Suite 401, Bethesda, MD 20892, 
<a href="/cdn-cgi/l/email-protection#cda0acbfb9ace3a5aca0a4b9b48da3a4a5e3aaa2bb"><span class="__cf_email__" data-cfemail="cba6aab9bfaae5a3aaa6a2bfb28ba5a2a3e5aca4bd">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.213, 
Research and Training in Complementary and Alternative Medicine, 
National Institutes of Health, HHS)

    Dated: January 29, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-02050 Filed 2-1-24; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
**EXHIBIT 10.2**

 

**DISCRETIONARY CREDIT NOTE**

 
| $943,666 |   | Minneapolis,  Minnesota |
|----------|--------|-------------------------|
|     |   | January  17, 2003       |

 

FOR VALUE RECEIVED,MEDICALCV, INC., a Minnesota corporation (the “Borrower”) promises topay to the order of PKM PROPERTIES, LLC, a Minnesota limited liability company(the “Lender”) at its office in Minneapolis, Minnesota or at such otherplace as may be designated from time to time by the holder hereof, in lawfulmoney of the United States of America, the principal sum of Nine HundredForty-Three Thousand Six Hundred Sixty-Six Dollars ($943,666) or so muchthereof as has been advanced by the Lender to or for the benefit of theBorrower pursuant to that certain Discretionary Credit Agreement, dated as ofthe date hereof, as amended from time to time, between the Borrower and theLender (the “Agreement”) and remains unpaid, together with interest onthe unpaid principal balance hereof from the date hereof until this Note isfully paid, at an annual rate of interest, calculated on the basis of actualnumber of days elapsed in a 360 day year, that shall at all times be equal tothe Floating Interest Rate, as provided in the Agreement, each change in theinterest rate herein to become effective on the day the corresponding change inthe Floating Interest Rate becomes effective.

 

Interest accruing on thisNote shall be due and payable on the last day of each month commencing January31, 2003, and at maturity or earlier prepayment in full.  The principal of this Note and all accruedinterest shall be due and payable on or before April 17, 2003.  Payments hereunder shall be applied first tothe payment of accrued interest and then to the reduction of principal.  The Borrower may prepay at any time and fromtime to time, all or any portion of the balance from time to time remaining onthis Note, without penalty or premium.

 

This Note is secured by theSecurity Agreement referred to in the Agreement and the Subordinated Mortgage,Security Agreement and Fixture Financing Statement, dated January 17, 2003given by the Borrower in favor of the Lender, and is issued pursuant to and issubject to the Agreement.

 

The Borrower agrees to payall costs of collection, including attorneys’ fees, in the event this Note isnot paid when due.  This Note is beingdelivered in, and shall be governed by, the laws of the State ofMinnesota.  Presentment or other demandfor payment, notice of dishonor and protest are expressly waived.

 

MEDICALCV, INC.

 

 
| By:    | /s/ Blair P. Mowery                           |
|--------|-----------------------------------------------|
|   | Blair P. Mowery,  Its Chief Executive Officer |

 

 

----
Exhibit 32.2

Statement

Pursuant to §906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. §1350, the
undersigned officer of Paperweight Development Corp. (the Company), hereby certifies that to his knowledge:



| | (1) | the Companys Quarterly Report on Form 10-Q for the quarter ended July 2, 2006 fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the
Securities Exchange Act of 1934, and
| | --- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | (2) | the information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------



|                       |  |                               |  |                                                                                 
|---------------------- |  | ----------------------------- |  | --------------------------------------------------------------------------------
|                       |  | PAPERWEIGHT DEVELOPMENT CORP.
|                       |  |                              
|Dated: August 14, 2006 |  |                               |  | /s/ Mark R. Richards                                                            
|                       |  | Name:                         |  | Mark R. Richards                                                                
|                       |  | Title:                        |  | Chairman, President, Chief Executive Officer and Interim Chief Financial Officer

This certification accompanies this Quarterly Report on Form 10-Q pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of the Securities Exchange Act of 1934.
----

----

|   | (1) | the Company’s Quarterly Report on Form 10-Q for the period ended July 3, 2011 fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended, and |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | the information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------|

|                              | PAPERWEIGHT DEVELOPMENT CORP. |
|-----------------------------------|-------------------------------|
|                              |                          |   |
| Dated:  August 11, 2011 |                          | /s/ Mark R. Richards  |
|                              | Name:                         | Mark R. Richards |
|                              | Title:                        | Chairman, President and Chief Executive Officer |
1491O-I3-PI

DEPARTMENT or TAANSPORTA TlON, 0l00ITl •••••••• "'"

'"

Federal Aviation Administration

14CFR Part 39

_.-

IDocket No. FA.4.-2010--0279~Directo..-ate Identifier 2009-NM-148-AO; Amendme t I

39_l0.'1.~?eD201o-~'~O7

.",,,,,,,, "~"'"

Airwortbiness Directives; Airbus Model A318. AJ 19. AnO, and A321 Series Airpla

AGE~CY: Federal Avialion AdminiSifaiion {FAA), Depanment of Transportation

(DOT).

ACTION: Final rule.

SUMMARY: We are adopting <lnew airwort~illcss directive (AD) for the products lis J/ oIJ ("l.-" 0

10

."

An extended de-bonding. ifnOl delecte~ and corrected, may dcgrade the

structural integrity oflhe nJdder. The loss of the rudder leads to

degradation of the handling qualities arid reduces the controllability of lhe

aeroplane.

Investigation has determined that the defccts reported on both nJddcrs

corresponded to areas that had been reworked in production. The

invcstigation confirmed thai Ihc defects were a result of de-bonding

belween the skin and honeycomb core.

Surface defects were visually detected on the l11dder of one A3l9 and one

A32l in-service aeroplane.

above. This AD results from mandatory continuing ainvorthiness information (r-.1C AI) A;J 1'4.-II ~

condition on an aviation product. The MeAl describes the unsafe condition as:

originated by an aviation authority of another country to identi fy and correct an lInsaf~

• • • • • • •

FAA Form 1360-'4.1 (5-89) OFFICIAL ALE COPY
Michigan Supreme Court

Lansing, Michigan

Robert P. Young, Jr., Chief Justice

Michael F. Cavanagh

Stephen J. Markman

Mary Beth Kelly

Brian K. Zahra

Bridget M. McCormack

David F. Viviano, Justices

I, Larry S. Royster, Clerk of the Michigan Supreme Court, certify that the

foregoing is a true and complete copy of the order entered at the direction of the Court.

 May 27, 2014

h0519

Order 

Clerk

May 27, 2014

148251

PEOPLE OF THE STATE OF MICHIGAN,

Plaintiff-Appellee,

v SC: 148251

COA: 311443

Muskegon CC: 11-060241-FC;

RYAN CHRISTOPHER GIERZAK, 11-060242-FH

Defendant-Appellant.

_____________________________________/

On order of the Court, the application for leave to appeal the October 17, 2013 

order of the Court of Appeals is considered, and it is DENIED, because we are not 

persuaded that the questions presented should be reviewed by this Court.
### THE THIRTEENTH COURT OF APPEALS

13

- 14

- 00291

- CR

Jennifer Pena v. The State of Texas
On Appeal from the 156th District Court of Live Oak County , Texas Trial Cause No. L

- 12

- 0036

- CR

- B

JUDGMENT THE THIRTEENTH COURT OF APPEALS, having considered this cause on appeal, concludes that the judgment of the trial court should be affirmed as modified by
this Court . The Court orders the judgment of the trial court AFFIRMED AS MODIFIED.
We further order this decision certified below for observance.

June 11, 2015
----

----

|   | (1) | the      Company’s Quarterly Report on Form 10-Q for the period ended October 4,      2009 fully complies with the requirements of Section 13(a) or 15(d), as      applicable, of the Securities Exchange Act of 1934, as amended,      and |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | the      information contained in the report fairly presents, in all material      respects, the financial condition and results of operations of the      Company. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                                    |                      |                                                |
|-----------------------------------------|---------------------------|-----------------------------------------------------|
|                                    | APPLETON      PAPERS INC. |
|                                    |                      |                                                |
| Dated:  November      6, 2009 |                      |                                                |
|                                    | Name:                     | Mark      R. Richards                               |
|                                    | Title:                    | Chairman,      President and Chief ExecutiveOfficer |
**Exhibit 32.2**

 

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

 

The undersigned, the ChiefFinancial Officer of Gladstone Capital Corporation (the “Company”), herebycertifies on the date hereof, pursuant to 18 U.S.C. §1350(a), as adoptedpursuant to Section 906 of The Sarbanes-Oxley Act of 2002, that the QuarterlyReport on Form 10-Q for the quarter ended December 31, 2003 (“Form 10-Q”),filed concurrently herewith by the Company, fully complies with therequirements of Section 13(a) or Section 15(d) of the Securities Exchange Actof 1934, as amended, and that the information contained in the Form 10-Q fairlypresents, in all material respects, the financial condition and results ofoperations of the Company.

 
| Dated:   February 17, 2004 |
|---------------------------------|
|                            |
|                            |
| /s/ Harry Brill                 |   |
| Harry Brill                     |
| Chief Financial  Officer        |

 

----
[Federal Register Volume 89, Number 21 (Wednesday, January 31, 2024)]
[Notices]
[Page 6119]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-01845]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Diabetes and Digestive and Kidney Diseases; 
Notice of Closed Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Diabetes and Digestive and 
Kidney Diseases Special Emphasis Panel NIDDK Application Review: RFA-
DK-23-017 (U01) and RFA-DK-23-018 (U24) Continuation of the Childhood 
Liver Disease Research Network (ChiLDReN).
    Date: March 21, 2024.
    Time: 9:00 a.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, NIDDK, Democracy II, Suite 
7000A, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: Cheryl Nordstrom, Ph.D., M.Ph., Scientific Review 
Officer, NIDDK/Scientific Review Branch, National Institutes of Health, 
6707 Democracy Blvd., Room 7013, Bethesda, MD 20892, 301-402-6711, 
<a href="/cdn-cgi/l/email-protection#e083888592998cce8e8f92849394928f8da08e8988ce878f96"><span class="__cf_email__" data-cfemail="680b000d1a11044606071a0c1b1c1a070528060100460f071e">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, 
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive 
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology 
and Hematology Research, National Institutes of Health, HHS)

    Dated: January 25, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-01845 Filed 1-30-24; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>